Bayer pharma chief sees no big acquisitions in near future
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...
Bayer’s Head of Pharma Oelrich Expects Business to Return to Growth in 2027
Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...
FiercePharma4d
JPM25: Bayer gears up for 'must-win battles' as Xarelto's decline is in full swing, pharma chief says
These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances
On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions ...
Bayer says menopause drug succeeds in breast cancer study
The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...
Bayer aims to expand presence in India with new therapies and strategic collaborations
Bayer's Global Capability Centre in Hyderabad contributes to R&D, data science, and AI-driven healthcare solutions, ...
Bayer to Scale Back Health Dealmaking Amid Push to Pay Down Debt
Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...
Cutting Middle Management: Bayer's Costly Experiment One Year Later
In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.
TMCnet3h
Leaps by Bayer Announces One of the Largest Global Surveys of Society's Attitudes Toward Breakthrough Technologies
As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch of one of the ...